Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim's Ofev, following new guidance from health technology assess
Pharma companies involved in the sale of heartburn therapy Zantac have won a key battle in litigation brought by patients who claim the drug caused them to develop cancer.
Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as its new head of medicine and chief medical officer, succeeding Mehdi Shahidi, who left the position earlier this year after three y
Boehringer Ingelheim was an early adopter of Medidata's electronic data collection (EDC) platform for clinical trials, and has now extended and expanded the contract.
